Pierre Fabre buys rights to Urovant's vibegron

Urovant Sciences has entered into an exclusive license agreement with French drugmaker Pierre Fabre to register and commercialize vibegron, trade named Gemtesa, for the treatment of overactive bladder (OAB) in the European Economic Area, UK, and Switzerland, with the first right of refusal for French-speaking countries of Sub-Saharan Africa, Turkey, and certain Eastern European countries. Urovant will retain full rights in the USA and certain other markets.

“We are thrilled to partner with Pierre Fabre, a leader in the international biopharmaceutical space,” said Jim Robinson, chief executive of Urovant Sciences, adding: “Their experience in the global OAB and benign prostatic hyperplasia (BPH) market make them uniquely suited to deliver vibegron to more patients who need it across Europe and surrounding areas.”

Financial terms of the accord